Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Understand wash sale implications for ERC-20 tokens in 2026 and practical tips to manage deductions and compliance.
16,848 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
As 2026 unfolds, the Ethereum Foundation confronts a notable wave of exits. An insider explains wave 2026 as a planne...
A retiree inherits a traditional IRA and sees Medicare premiums rise in 2026 due to a 2024 income spike, exposing the...
A realized gain of $40,000 in 2025 could push 2027 Medicare costs higher for some retirees due to the two-year lookba...
As rates stabilize near mid-4% levels in 2026, PFFA’s 2.11% fee is put to the test against cheaper passive peers. The...
In 2026, the best real estate deals go to those who are proactive, data-driven, and connected. This guide shows rooki...
As 2026 unfolds, lawmakers and the Social Security Administration weigh reforms that could reduce benefits for 66-yea...
Two clean-economy names, two distinct plays: Brookfield Renewable and Clean Harbors offer differing traps and rewards...
Two funds track the same Nasdaq-100 index, but a lower expense ratio gives Invesco NASDAQ 100 ETF a quiet advantage f...
As GLP-1 therapies reshape obesity treatment, investors eye the best weight loss drug stock bets for 2026. This guide...
A disrupted energy flow landscape is lifting a U.S. midstream stock and with it the focus on safe, high-yield income....
As 2026 unfolds, investors face a choice between DoorDash and Lyft. This article breaks down growth, margins, and ris...